{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-269431","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2026-06-12T20:11:14+00:00","discovered_at":"2026-06-12T20:12:00.360467+00:00","generated_at":"2026-06-12T20:24:33.606975+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Vor Bio stockholders approve amended 2021 equity plan and elect two Class II directors","bullets":["Andrew Levin, M.D., Ph.D. elected with 25,797,081 for, 120,813 withheld; Fouad Namouni, M.D. elected with 22,825,938 for, 4,091,956 withheld.","Amended 2021 Equity Incentive Plan approved (20,146,430 for, 6,767,428 against, 4,036 abstain).","Plan amendment expands evergreen provision to include pre-funded warrants in share reserve calculation and adds automatic full vesting of time-based awards upon employee death.","Ratification of Ernst & Young as independent auditor for FY 2026 passed (33,877,004 for, 133,499 against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-269431","json":"https://secwatch.observer/filing/0001193125-26-269431.json","markdown":"https://secwatch.observer/filing/0001193125-26-269431.md","text":"https://secwatch.observer/filing/0001193125-26-269431.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526269431/0001193125-26-269431-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526269431/vor-20260611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T20:24:33.606975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c11780085cb482f63837f3bda2842368253a252","claim":"Vor Biopharma Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-12-31 meeting.","evidence_excerpt":"Proposal 3 - Ratification of Selection of Independent Registered Public Accounting Firm The Stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, by the following votes: For Against Abstain 33,877,004 133,499 1,501","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526269431/0001193125-26-269431-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"69694f8fa33c0ed32f41bbd2fa7bb265dff0ba8d","claim":"Vor Biopharma Inc. shareholders approved Election of Two Class II Directors Andrew Levin, M.D., Ph.D. and Fouad Namouni, M.D..","evidence_excerpt":"Proposal 1 - Election of Two Class II Directors Andrew Levin, M.D., Ph.D. and Fouad Namouni, M.D. were each elected to serve as a member of the Board until the 2029 Annual Meeting of Stockholders and until his successor is duly elected or qualified, or, if sooner, until the director’s death, resignation or removal, by the following votes: Nominee For Withheld Broker Non-Votes Andrew Levin, M.D., Ph.D. 25,797,081 120,813 7,094,110 Fouad Namouni, M.D. 22,825938 4,091956 7,094,110","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526269431/0001193125-26-269431-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"c11074ff8fcd55c405862309c93724634ce468d8","claim":"Vor Biopharma Inc. shareholders approved Amendment and Restatement of the Company's Amended and Restated 2021 Equity Incentive Plan.","evidence_excerpt":"Proposal 2 - Amendment and Restatement of the Company's Amended and Restated 2021 Equity Incentive Plan The Stockholders approved the Amended 2021 Plan by the following votes. For Against Abstain Broker Non-Votes 20,146,430 6,767,428 4,036 7,094,110","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526269431/0001193125-26-269431-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}